| Title |
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
|
|---|---|
| Published in |
Biologics: Targets & Therapy, January 2013
|
| DOI | 10.2147/btt.s31474 |
| Pubmed ID | |
| Authors |
Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta Nannini |
| Abstract |
The aim of this study was to evaluate the proportion of patients with ankylosing spondylitis maintaining clinical remission after reduction of their subcutaneous etanercept dose to 50 mg every other week compared with that in patients receiving etanercept 50 mg weekly. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 25% |
| Canada | 1 | 25% |
| Spain | 1 | 25% |
| Australia | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Unknown | 57 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 14% |
| Other | 6 | 10% |
| Student > Master | 5 | 9% |
| Professor | 4 | 7% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 13 | 22% |
| Unknown | 18 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 52% |
| Nursing and Health Professions | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Mathematics | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 19 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2021.
All research outputs
#6,275,904
of 25,373,627 outputs
Outputs from Biologics: Targets & Therapy
#83
of 284 outputs
Outputs of similar age
#60,860
of 288,991 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 7 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,991 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.